Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• The amyloid cascade hypothesis posits that amyloid-beta (Aβ) self-assembly causes Alzheimer's disease (AD).
• Numerous clinical trials targeting Aβ have failed, leading some to question the hypothesis.
• The precise mechanisms of action for Aβ-targeting therapies are difficult to ascertain.

Purpose of the Study:

• To investigate the mechanisms of action of four clinical-stage anti-Aβ antibodies.
• To quantify the impact of these antibodies on Aβ aggregation kinetics and oligomer production.
• To correlate antibody binding characteristics with their effects on Aβ.

Main Methods:

• Kinetic analyses of Aβ aggregation.
• Quantitative binding measurements of anti-Aβ antibodies.
• Assessment of antibody influence on oligomeric aggregate formation.

Main Results:

• Compared to gantenerumab, bapineuzumab, and solanezumab, aducanumab uniquely and significantly reduced the flux of Aβ oligomers.
• Antibody effects on aggregation were linked to their affinity and stoichiometry for monomeric and fibrillar Aβ forms.
• Detailed kinetic and binding data were obtained for all four antibodies.

Conclusions:

• Aducanumab's distinct mechanism in reducing Aβ oligomer flux provides a potential explanation for its unique therapeutic profile.
• This study offers a quantitative framework for understanding anti-Aβ antibody mechanisms.
• Findings may guide future therapeutic strategies for Alzheimer's disease targeting Aβ.